Read More 

About Me

You got a dream, you gotta protect it. People can't do something themselves they wanna tell you, you can't do it. If you want something, go get it.
- The Pursuit of Happyness.

My Name is Kai Gu

Graduated from Zhejiang University of Technology, majoring in biochemistry. 
For personal interest, I select bioinformatics by self-learning as my first career at a biotech in 2016. Afterwards I went to a famous IVD company as a statistical analyst and lead bio-statistician role for clinical trials. For now, I'm taking the lead statistical programmer role in drug trial, including non-oncology and oncology studies at a bio-pharma company, to learn more about drug fields.


  • The first purpose for writing blogs is to push myself to learn more about Bioinformatics because I'm inter-professional, and  need to learn more and faster to get the higher grade.
  • Otherwise I'd like to keep notes and share any ideas in my work and interest, which motivates me to keep the blog going, and inspires me all the time.


ShangHai, China



  • Let me know what's interdisciplinary Biology and Computer, and how to use programming and statistical method to resolve questions.
  • The precious research experience teaches me how to conduct a basic research, like posing a question and exploring it. 

Sr. Statistical Analyst - Lead Bio-statistician(IVD)

  • Let me know what the clinical data is in the submission stage of clinical trial, and how to deal with it through the programming by SAS&R. Especially how to build maintainable and robust R packages as well as Shiny modules with the tech stack in the multi-collaboration mode.
  • Let me know what's the clinical protocol, and how to take the role and responsibilities as a biostatistician in the clinical trial.
  • Learning more statistical methods and designs in the clinical trial, and how to carry out a clinical from the bio-statistician perspective.

M. Statistical Programmer (Pharma)

  • Let me know how to develop non-oncology and oncology drugs, as well as carry out clinical trials. Even if I'm just a small part of it, I'm still curious about the overall project.
  • Learning the protocol and SAP, and find out where are the difference between IVD and drug trials.
  • Learning the data structure of drug trials, from raw data to SDTM and ADaM, how to do the statistical analysis, and what's the endpoint of each study.


It is unknown where my career will finish.
Despite the fact that I can pick up information rapidly and perform effectively, I'm not the smart person.

“We live and learn, or, perhaps more importantly we learn and live.”
— Terry Pratchett


Collaborative research, as a statistician.

Wei Nie, Mi-Die Xu, Lu Gan, Yi Zhang, Jie Qian, Kai Gu, Xue-Yan Zhang,... & Bao-Hui Han (2019) Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy, J Immunother 43(6):189-195 [PMID: 32209830]

Wei Nie, Jie Qian, Mi-Die Xu, Kai Gu, Fang-Fei Qian,... & Bao-Hui Han (2020) Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel, JNCCN 18(5):582-589 [PMID: 32380463]

Wei Nie, Jie Qian, Mi-Die Xu, Kai Gu, Fang-Fei Qian,... & Bao-Hui Han (2020) A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab, Oncoimmunology 9(1):1731072 [PMID: 32158623]

Wei Nie, Lu Gan, Xin Wang, Kai Gu, Fang-Fei Qian,... &Bao-Hui Han (2021) Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation, Oncoimmunology 10(1):1865670 [PMID: 33537171]

Shixiang Wang, Yi Xiong, Kai Gu, Longfei Zhao, Yin Lia, Fei Zhao, Xuejun Li, Xue-Song Liu (2021) UCSCXenaShiny: an R package for exploring and analyzing UCSC Xena public datasets in web browser, Bioinformatics. [PMID: 34323947] DOI: 10.1093/bioinformatics/btab561

Anning Xiong, Wei Nie, Yan Zhou, Changhui Li, Kai Gu, Ding Zhang,…& Xueyan Zhang (2021) Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients, Front. Immunol. 12:708558. doi: 10.3389/fimmu.2021.708558